<SEC-DOCUMENT>0001193125-20-092017.txt : 20200331
<SEC-HEADER>0001193125-20-092017.hdr.sgml : 20200331
<ACCEPTANCE-DATETIME>20200331092209
ACCESSION NUMBER:		0001193125-20-092017
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20200330
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200331
DATE AS OF CHANGE:		20200331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		20759882

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d852496d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amrn="http://www.amarincorp.com/20200330" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2020-03-30_to_2020-03-30">AMARIN CORP PLC\UK</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-03-30_to_2020-03-30">00-0000000</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityAddressPostalZipCode_duration_2020-03-30_to_2020-03-30" name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-03-30_to_2020-03-30">2</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CityAreaCode" name="dei:CityAreaCode" contextRef="duration_2020-03-30_to_2020-03-30">353 (0)&amp;#160;1</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-03-30_to_2020-03-30">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-03-30_to_2020-03-30">0000897448</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amrn-20200330.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-03-30_to_2020-03-30"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000897448</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-30</xbrli:startDate> <xbrli:endDate>2020-03-30</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:6pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">WASHINGTON, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:12pt">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-03-30_to_2020-03-30">8-K</ix:nonNumeric> </span></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section&#160;13 or 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt:datemonthdayyearen">March&#160;30, 2020</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:12pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amarin Corporation plc</span> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-03-30_to_2020-03-30">0-21392</ix:nonNumeric> </span></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not applicable</span> </p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">of incorporation)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(I.R.S. Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)</p></td></tr></table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:50%;"></td>
<td style="width:1%;"></td>
<td style="width:48%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-03-30_to_2020-03-30">77 Sir John Rogerson&#8217;s Quay</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-03-30_to_2020-03-30">Block C</ix:nonNumeric>,</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2020-03-30_to_2020-03-30">Grand Canal Docklands</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-03-30_to_2020-03-30">Dublin <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-03-30_to_2020-03-30">2</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:countrynameen">Ireland</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Not applicable</p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Zip Code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Registrant&#8217;s telephone number, including area code: + <span style=" -sec-ix-hidden:Hidden_dei_CityAreaCode">353</span> 1 <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-03-30_to_2020-03-30">6699 020</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Not Applicable</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Former name or former address, if changed since last report</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12) </span></td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b)) </span></td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c)) </span></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:35%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:32%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-03-30_to_2020-03-30">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1)&#160;Ordinary Share of Amarin Corporation plc</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-03-30_to_2020-03-30">AMRN</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:exchnameen">NASDAQ Stock Market LLC</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR &#167;<span style="white-space:nowrap">240.12b-2). </span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Emerging growth company&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-03-30_to_2020-03-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:8pt"></p> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:9%;vertical-align:top;white-space:nowrap;">Item&#160;8.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Other Events.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">On March&#160;30, 2020, Amarin Corporation plc issued a press release titled &#8220;Amarin Comments on Ruling in VASCEPA<sup style="font-size:85%;vertical-align:top">&#174;</sup> ANDA Litigation.&#8221; A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:9%;vertical-align:top;white-space:nowrap;">Item&#160;9.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d) Exhibits </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Exhibit<br />No. </p> </td>
<td style="vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Description </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d852496dex991.htm">Press release, dated March&#160;30, 2020 </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive Data File (embedded within the Inline XBRL document) </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:46%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:2%;"></td>
<td style="width:1%;"></td>
<td style="width:45%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;&#160;&#160;Date: March&#160;30, 2020 </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td colspan="3" style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Amarin Corporation plc </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:center;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:center;padding:0;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ John F. Thero</p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">John F. Thero </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">President and Chief Executive Officer </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d852496dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Comments on Ruling in VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> ANDA Litigation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;30, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DUBLIN, Ireland and BRIDGEWATER, N.J.,
March&nbsp;30, 2020 (GLOBE NEWSWIRE) &#151; Amarin Corporation plc (NASDAQ:AMRN) today commented on the United States District Court for the District of Nevada&#146;s ruling in favor of the generic companies in the company&#146;s patent litigation
against two filers of abbreviated new drug applications, or ANDAs, for Amarin&#146;s VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsule franchise. Based on Amarin&#146;s review of U.S. Food and Drug
Administration&#146;s (FDA&#146;s) website, an ANDA for VASCEPA has not been approved, which would be required for launch of a generic product in the United States. The company thus does not believe there is an impending generic launch by the
litigants that would compete with VASCEPA at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Amarin strongly disagrees with the ruling and will vigorously pursue all available
remedies, including an appeal of the Court&#146;s decision and a preliminary injunction pending appeal to, if an ANDA is approved by FDA, prevent launch of generic versions of VASCEPA in the United States,&#148; said John F. Thero, president and
chief executive officer of Amarin. &#147;At Amarin, we have a strong balance sheet with capacity and flexibility, and we plan to fight to protect our VASCEPA franchise for the benefit of our patients, physicians, the broader healthcare community and
our investors. We believe we are favorably situated to obtain an injunction against generic launch pending appeal, subject to our posting a bond to secure generics&#146; lost profits in the event that generics prevail on appeal. As we work to take
all legal actions necessary to defend and protect our intellectual property, we will continue to press forward with our educational and promotional efforts for VASCEPA in treating indicated patients at high risk of cardiovascular events, such as
heart attack and stroke. After we determine the outcome of our effort to prevent a generic launch (if an ANDA approval is obtained), we expect to provide an update on how we would adjust certain promotional activities for VASCEPA in the United
States.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Geographies outside the United States in which VASCEPA is sold and under regulatory review are not subject to this litigation and judgment.
No generic litigation is pending outside the United States. VASCEPA remains available by prescription in Canada, Lebanon and the United Arab Emirates. In Canada, VASCEPA has the benefit of eight years of data protection afforded through Health
Canada (until the end of 2027), in addition to separate patent protection with expiration dates that could extend into 2039. Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA
in the European Union, China and the Middle East. Ten to eleven years of market protection is anticipated due to regulatory exclusivity in the European Union subject to pending VASCEPA approval expected later this year, in addition to pending patent
protection that could extend into 2033. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively
improve cardiovascular health. Amarin&#146;s lead product, VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. Amarin,
together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union and the Middle East. For more information about Amarin, visit <U>www.amarincorp.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Disease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardiovascular disease is
an enormous and growing medical issue worldwide.<SUP STYLE="font-size:85%; vertical-align:top">1,2</SUP> In the United States alone, a heart attack, stroke, death or other major cardiovascular event is experienced every 14 seconds.<SUP
STYLE="font-size:85%; vertical-align:top">3</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Controlling bad cholesterol, also known as <FONT STYLE="white-space:nowrap">LDL-C,</FONT> is one way to
reduce a patient&#146;s risk of experiencing a cardiovascular event. However, even with the achievement of target <FONT STYLE="white-space:nowrap">LDL-C</FONT> levels, millions of patients still have significant and persistent cardiovascular risk,
especially those patients with high triglycerides. Statin therapy has been shown to control <FONT STYLE="white-space:nowrap">LDL-C,</FONT> thereby reducing the risk of cardiovascular events by <FONT STYLE="white-space:nowrap">25-35%</FONT> &#150;
but that still leaves <FONT STYLE="white-space:nowrap">65-75%</FONT> of risk remaining.<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> People with high triglycerides have 35% more cardiovascular events compared to people with normal (in
range) triglycerides taking statins.<SUP STYLE="font-size:85%; vertical-align:top">5,6,7</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA (icosapent ethyl) capsules are the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-and-only</FONT></FONT> prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was
initially launched in the United States in 2013 based on the drug&#146;s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe
(<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million times and is covered by most major medical insurance plans. The new, cardiovascular risk indication for
VASCEPA was approved by the FDA in December 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indications and Limitation of Use</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA is indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary
revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 150 mg/dL) and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established cardiovascular disease or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diabetes mellitus and two or more additional risk factors for cardiovascular disease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an adjunct to diet to reduce TG levels in adult patients with severe
(<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 500 mg/dL) hypertriglyceridemia. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect of VASCEPA on the risk for pancreatitis in
patients with severe hypertriglyceridemia has not been determined. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or
any of its components. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring
hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of&nbsp;&nbsp;&nbsp;&nbsp;atrial fibrillation or atrial flutter. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic
reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled
trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common adverse reactions in the cardiovascular outcomes trial (incidence
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>3% and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial
fibrillation (5% vs 4%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common adverse reactions in the hypertriglyceridemia trials (incidence <U>&gt;</U>1% more frequent than placebo):
arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events may be reported by calling
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents for bleeding should be
monitored. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies
section of the prescribing information for VASCEPA, as set forth below: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effect of VASCEPA on Time to First Occurrence of Cardiovascular
Events in </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patients with Elevated Triglyceride Levels and Other Risk Factors for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cardiovascular Disease in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA</B><br><B>vs Placebo</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N =<BR>4089<BR>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence&nbsp;Rate<BR>(per&nbsp;100&nbsp;patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N =<BR>4090<BR>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence&nbsp;Rate<BR>(per&nbsp;100&nbsp;patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Hazard&nbsp;Ratio<BR>(95% CI)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Primary composite endpoint</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization
for unstable angina <FONT STYLE="white-space:nowrap">(5-point</FONT> MACE)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">705<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(17.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">901<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(22.0)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.75<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.68,&nbsp;0.83)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key secondary composite endpoint</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death, myocardial infarction, stroke
<FONT STYLE="white-space:nowrap">(3-point</FONT> MACE)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">459<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(11.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">606<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(14.8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.74<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.65, 0.83)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other secondary endpoints</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatal or <FONT STYLE="white-space:nowrap">non-fatal</FONT> myocardial infarction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">250<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(6.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">355<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(8.7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.69<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.58, 0.81)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emergent or urgent coronary revascularization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">216<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(5.3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">321<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(7.8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.65<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.55, 0.78)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death <SUP STYLE="font-size:85%; vertical-align:top">[1]</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">174<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(4.3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">213<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(5.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.80<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.66, 0.98)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hospitalization for unstable angina
<SUP STYLE="font-size:85%; vertical-align:top">[2]</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">108<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(2.6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">157<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(3.8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.68<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.53, 0.87)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatal or <FONT STYLE="white-space:nowrap">non-fatal</FONT> stroke</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">98<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(2.4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">134<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(3.3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.72<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.55, 0.93)</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[1]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes adjudicated cardiovascular deaths and deaths of undetermined causality. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[2]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Determined to be caused by myocardial ischemia by <FONT STYLE="white-space:nowrap">invasive/non-invasive</FONT>
testing and requiring emergent hospitalization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT <U>WWW.VASCEPA.COM</U>.
</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including expectations regarding plans for appeal, to obtain an injunction against generic launch
pending appeal, subject to our posting a bond to secure generics&#146; lost profits in the event that generics prevail on appeal, to update on the degree to which we would scale back certain promotional activities for VASCEPA in the United States,
to otherwise seek to maintain exclusivity for VASCEPA in the United States and elsewhere based on, as applicable, litigation, regulatory exclusivity and issued and allowed patents and the expected expiration dates of those patent applications and
issued patents to correspond with associated exclusivity protection and plans to continue commercialization efforts in the United States. There can be no guarantee we would be successful in any of such efforts. These forward-looking statements are
not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally
with the commercial success of pharmaceutical products such as VASCEPA; the risk of loss in the planned appeal of the Court&#146;s judgment and in seeking preliminary injunction; that patent applications may not result in issued patents, and that
issued patents may not prevent competitors from competing with VASCEPA; the risk that new competitors may further challenge the exclusivity afforded by the same patents at issue in this litigation through a new litigation or otherwise seek to gain
marketing approval for generic versions of VASCEPA or branded competitive products based on new clinical studies; and the risk that trade secrets may not be maintained and that other circumstances that create barriers to competition with VASCEPA may
not last. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In addition, Amarin&#146;s ability to effectively commercialize VASCEPA will depend in part on its ability to continue to
effectively finance its business, efforts of third parties, its ability to create market demand for VASCEPA through education, marketing and sales activities, to achieve market acceptance of VASCEPA, to receive adequate levels of reimbursement from
third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, and to comply with legal and regulatory requirements in connection with the sale and promotion of VASCEPA. A further list and description of
these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form
<FONT STYLE="white-space:nowrap">10-K.</FONT> Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or
revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors
and others should note that Amarin communicates with its investors and the public using the company website (<B><U>www.amarincorp.com</U></B>), the investor relations website (<B><U>investor.amarincorp.com</U></B>), including but not limited to
investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from
time to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these channels, or any other website that may be accessed from its website or these channels, shall not be
deemed incorporated by reference in any filing under the Securities Act of 1933. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor and Media Inquiries: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com</U> (investor inquiries) <U> </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>PR@amarincorp.com</U> (media inquiries) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solebury Trout </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (646)
<FONT STYLE="white-space:nowrap">378-2992</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@soleburytrout.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association. Heart Disease and Stroke Statistics &#150; 2019 Update: A Report from the American
Heart Association. Published January&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association / American Stroke Association. 2017. Cardiovascular disease: A costly burden for
America projections through 2035. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association: Heart Disease and Stroke Statistics &#151; 2019 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">At-a-Glance.</FONT></FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia
management. J Am Coll Cardiol. <FONT STYLE="white-space:nowrap">2018;72(3):330-343.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am
J Cardiol. <FONT STYLE="white-space:nowrap">2016;118:138-145.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events,
medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from
epidemiology, genetics, and biology. Circ Res. <FONT STYLE="white-space:nowrap">2016;118:547-563.</FONT> </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amrn-20200330.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-1 Build:20200228.30 -->
<!-- Creation date: 3/31/2020 5:07:42 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:amrn="http://www.amarincorp.com/20200330"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amarincorp.com/20200330"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amrn-20200330_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amrn-20200330_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>amrn-20200330_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-1 Build:20200228.30 -->
<!-- Creation date: 3/31/2020 5:07:42 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>amrn-20200330_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-1 Build:20200228.30 -->
<!-- Creation date: 3/31/2020 5:07:42 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amrn-20200330.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d852496d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d852496d8k.htm">d852496d8k.htm</File>
    <File>amrn-20200330.xsd</File>
    <File>amrn-20200330_lab.xml</File>
    <File>amrn-20200330_pre.xml</File>
    <File>d852496dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>7
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d852496d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d852496d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amrn-20200330_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amrn-20200330_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amrn-20200330.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 6
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "amrn",
   "nsuri": "http://www.amarincorp.com/20200330",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d852496d8k.htm",
      "contextRef": "duration_2020-03-30_to_2020-03-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d852496d8k.htm",
      "contextRef": "duration_2020-03-30_to_2020-03-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>8
<FILENAME>0001193125-20-092017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-092017-xbrl.zip
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MD\U);F_Z$]]<-1L'?_X'4$L#!!0    ( ,1*?U BOE'6FP8   M*   5
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M"\R[ *>POJR5I%M>+@>BK2[O@SI:7,XW0#'!>X:\NHPOHVYQV5R+RP88VC;
M\.0:8&C: $,7#3#\>@TP67-G#8 DP[@!:K6X;("1;0.,3JX!1J8-,'+1 *.O
MV #2#^Z> Y"$F+= O1KT)E!WD]Z+"5^SHUJ@G'X*#:"1H[/_4QB:^9]#.K)^
M>O>/"U!$N*;'%E!G>3,5^&;/7AD?Y_0B]R1L_DR(UN-9#)[!RWBNW)UQ(!L;
ML_!:5Q^J'L/0ZEWKT?V<LX9K+OMY+1FY4@#7'[<QL!X+R;PI.*3H6&LN;NHM
M>[9)T1AV_5/0)"'LDB\6*Y:_G3 V]6Q%<DO&K9?":X)L+%P#B.3CG %V*:R]
M[+#PLJ&;5H]AZ@<>T8 FE,W>^K(6ZD>FCM9EMF3G&A&\*L+&R%5H2"Y^@H<"
MW]K"KDHN^[=1W1CFO1=$]0J1YDC?J* ^4";>/SZ:CQ)U""V9V4 4/Q1I8^Y#
MJ$@FES10YH&,"%(F:[N[%E&V_9%*'#3 ;1ROB+!O PW.:31#M4!]2^S%(S9&
M!;:K]LCHG':)(T6UO=)(%LK 0X*5G+.V@^%T0I/(^ TR^WEM#3M5 KC^N-6@
MH\7"&G-R<)#HD,+;3SE.ZMV9<1H4C6'7B?#5%S8\;!=3;CR:/TMJR:CZTKGF
MH(U%-4!(_LR1(8.V]J:#0LO&-*T6\QIZO0GF4C-I\CEV?6[+UU*M$%X=@W%-
MW<?#OJX6##B?8W=7M_;Z:E@\WHV5ZP41,]E!OPF^3N9R2%GZK.']E0J(5F^S
MU,OB!T/M;[K4P.+>>RF((&."G KI%HQ#&9H[,:9:RCONY);Z#J-\%\V^R4?N
M^1]02P,$%     @ Q$I_4#J\N178!   A2X  !4   !A;7)N+3(P,C P,S,P
M7W!R92YX;6S5FE%SXC80Q]]OYKZ#ZGMI9VJ,[:1W84)N*$DZ3$F. :[M].5&
MV MH*DL>203X]I4,ZF$P*22]CI6' +)V]=_]R4(K?/UQE5'T!$(2SMI>V&AZ
M"%C"4\)F;6\A?2P30CPD%68IIIQ!VUN#]#[>O'US_9WOH]O[WB/RT5RI7+:"
M8+E<-M(I89+3A=(N92/A68!\W_;OCC^CWS;#M= 0*& )*&I&33]$/R\(35OF
M0S.*/C3BYJZ= &P<HA0K:*$XB,/ ]$27K>;[UD6$!@_H#DL%@J$QR6#7E.=K
M069SA;Y/?BC&0K><,: 4UNB>,,P2@BD:6<D_HAY+&JA#*1H:,ZEU2A!/D#:V
M7BEA?[7,OXE1C]Z^0?I/)Y+)HK7MF71LL[&:"-K@8J;5-N/ &GF[-JL#HV5<
MF(175U=!<;7<7Y*JWGJ ,/CCH3]*YI!A7T/0T)*]H;2:5/UCO2ON,MA<M/TE
M:<G"4Y\G1>I/" L=[6$^^;:;;YK\,/+CL+&2J7=CAMQD57 *0Y@B\_IYV"N-
MB3,LB)Z<(B]F5<&_&<?-0.$59SQ;!\8JN.7)(@.F[&N'I7=,$;7NL2D761&+
MAXJTMN8"IFT/9X+YUIM1]&ZH'7TYQY%:Y_K6D"3+*7@HV(DH%WKV,%7T[NN&
MD@&L%+ 44NO&!/#-8K[9D-U.7YZ4<F#OX *;A*0QXT]!"D2/&%Z9-[YYXS?#
M+;1WNNE+E^NEHS.12N!$E5-!S:SAPC92/ ':]BJ,@O]>UB;T(<R(&82I1YS!
MJ>JJ;<LB=Y%V1%+RC$5BO>JW!SS+=\6V1Y!CH?WYR5PO@-9Z*GA6F;#M:/PY
MO5RD(-I>%#7THN"A7! N=#?=XJ&%U))X;L1C:J[!%(2 M+])PE&QA5*]P$HH
M>GY#<F.\ZJ4Z(61*-DO/XR*;@#@/X5$G=6=Y5+B%&CL)M9.F.M5RP/77$OV3
MY%V>GGE35GNH.\YJU9;EA6,LNR8BO1<[AU[9IKZ\RCHMH4O'"'7T]W]J]@#W
M%,].1;1G5%]&>T(MI)\<@[19&KHZ#H%I3^\ 5[_"^KS5\,"XOM"."+;PWCL&
MSVZRQSJ9IS(KV]0755FG)73E**$!:,6Z$DIOL3H;U9YQ_9GM"=["TQ6M6_!L
MX6J*7BZ*#(]THJ'+%WH!69^_;_P75_4%>Y)\BSET$O,]H?"2ZF[7KNX =[5:
M6FX6YMM:9OO2)PS"%Y5P90=UYU<IVH)TNAC?"2EZ+<C(19#15Y"N5>+'0HI?
M"S)V$63\%:1K!7LI)',&\4F,^9*]"..NN2,0=R5;A&Z6\S:@S>[L9?RLK2OP
MK%Y+SK5:WORX20=SSL[<A1[:U9?8H59+ZX-CM'[7*A6P+L^R!=O^.B)/17;$
MN+[<C@BV\%P[E!EQ2A*B")L]Z!I6$"/P-')5EO7%5J5VR^S"M;.8@0 S_8 E
M4)P*FH<5Q*?I]/2%\CD/]67XG&K+TK4#E[V8>E(N0+R>:(4?9[A6:+=T73N@
M&4&R,$+#:#(FBIY\1'IH5U]ZAUHM+==.8<8"FT<L1^MLPD_^&MPSJB^G/:$6
MDFLG+':ZW:V2.68S..<QLFK;^B*KUFO)N7FD<I>!F.EY^(O@2S77ZWZ.V9EE
M^1$7]>7XK&R+\W\X7KD.#E+3UPWFZ>G-%?/// NL6_X&4$L#!!0    ( ,1*
M?U *)<#A.0\  +YR   .    9#@U,C0Y-F0X:RYH=&WM'6EOXDCV^TK['TJT
M9A2TS6'(P9$P8@C=PTY",I#9&:U6:A5V ;5M;$]5D<#^^GVO;(,!$PSDZC21
M0FSJ>J_>_>K(^4^3D4WNF9#<=2Y21C:?(LPQ78L[@XO46/4SI13YJ?;WOYT/
M%52$RHZL6(Q?I(9*>95<;M(3=E8R,SMP[W-0D"ODC7(F;V2*1BJH/I89-?68
MG+7I4]G+NF*0"TMB&CFNXXQ'LR8/#P]9/10VLY3(8;L<5,I +2:X&;:;V-SY
MNM#LH:@;&>5R.:=+PZHK-6<#%/+Y8@Z+>U2RL#H="6>A.AU1P6&NA)<UW1$T
MPF;%_ P2R>/@@$I&[L_KJZXY9".:X8Y4U#%GHXR56 M3.0>E844NW>."<?8(
M D&-68/)NKH&U'4 7?;GSYVK>7457W]>-:<$=63?%2.J@'VPIY-,OI IG$8Z
MR0!S+'04,LNF?DH1;I#<C.<X*,#JQB+S8!7^V,PL33J66DL\'50^S?F%0=7U
MG(7RD=*"PJB%?Q57-JN5,K^>Y_Q'^&[$%"780X;]->;W%ZF&ZRCFJ,P=L'.*
MF/[;14JQB<KI'DD.V^6"3@DAYSW7FN+CN<7OB513FUVD+"X]FTY1:EBJ1L[Y
MI((MF B>N64QQW^&*FU?9 BW+E*_Z*(O(+E?F@[ .>VP 9=($-6F(X#)@4\8
M@/%*?+F&>:(ZK ^UQD)3\ O*0B9?S!3S7Y0;>4O5ZM?U3JM-&C>=6W)[U?C/
M[S ]"U E@_*.3EKPC>)];NHAH7:/B55PUU;<$NX\//D_.\%;MRS!I+QU@?'L
M?W.OX5KLR^9A5]")ZV=K7 I;HM# @06C_F!SD!:_WQ*(XDF1'.73/]*15_U@
MG.:KQB:HY@/71\RQX%=]LNE@ZY'[U)9L)RHV8$A![99CL<FO;+I*GI4*6W-9
M/E\JGQT?EU;ARRT)LF!])L!6,PGO:*PJ4IL4&(MH.U=!&WF1DGSDV:CJ]'=#
M@:"@+<N$!BL[D5983(4I7-0HB<WB,QC<VGEN$9\ ^P6,];MTQ\)_U2J_$DRW
MIEZ"Z0Z;,4V\V2L/% 831(/ 8NU7H_7K(L&6&R/4L?U[0%'7FKV"* MU216K
MS6$+6\[+YK!::^J&);-A9^/D%F9G-IOSV<M%#48.#$MMP;STH6%&\O^QBI'W
M5/6!6VI8*65/N%,%'VC G4J>T+%R4XO-<+ ,M?G J9@P!:!UH=P+2]'Z9X:,
M#X:JDL^>0+\]5P $F9ZKE#O"[_+>A$C7YA;YX.O>8&@CG_\A&#FC7*^"0 6O
M86-/I6H_:KURGO-J,3@E!Z[XM* 5XD&;#;V,R"3:W2DVQF:1!IHZ?3KB]K1R
MQT=,DC9[(!UW1)VJ+GOP\>BYME5=0;L:(6XI;AZ7L$G5?F^W[IJ7I'M7OVMV
M7QF6;K/Q>Z=UUVIV2;U]29I_-GZIMS\WP;^XOFYUNZV;]K,!6$@$X!_U[B^M
M]N>[F_9'<IEM9$DA?W)<]H':B1M/YX/8K*\J*'=+[&FLX<T"A'<G,^X4NCO=
M/ )T+%J31QGV>6D^688N5?MTT[DFY]*C3@C"PY KEH%O3 9&\T%0#Z1DG?=P
MZ9IC=!XB/G=R"ZW]^173C+#4#D1-+"<Q1 4Y[C3;=Z33O+WIW+VRU-Z.A1Q#
MB$.42[K,1)[PY\HH$E<0X^3(2K\RB&Z?J"%#Z,:"*P[C-2?FD#H#1NJF(E!L
ME(O'+PID#%71(4%8.LQSA2)'X7N3@D/"I"+->^@Z*&96NK+>Z0_%]E9[-4W?
MV=E6?HF?9;A(\8FJ6-#!")H/+3J=,@JN9:IV#1[PT*=U,?^18--E>3_(>1Q'
M%(Z3<<2BXB:8'LKP2<:/;"J;TA&UNDZZD88K@&,TL8EGFX$&)L_&[K$>YHI,
M'C4G%&0/>1:97,Q@)U02Z3$3XP*+ /Q<20+2"CPOTN^ GS#=17LV(R:S;33#
M.GT,XH;O'K6L\-V'33^NQ!:EN9]MNK9-/<DJDGD4R,S"@J#O2IR[O9[K5N=H
M!>V4CX3P_U@SQT*/4CS^H8INM[*"XNCS4M7B4M7%8N/1TDAC^ A@$6$=CPY8
MIB<8_8I98X@S*_3>Y=8RFZ:6NKYG0G&3V@%'P9Q4 XK +*9>4US6JGI?]%LZ
MMQY(>5<!%S3<L:/$=)=\4U3QH\ZI,&M A2?<>]/O%)5_TQG8U+$(_OY!;2;C
M5'\,]6*F>"XD26J_$8+LX53[)/O$;;9K@C53,(KEF-3DW+G^;F9^HU5<E]6N
MM5VP-9YGP]>@CJ-F<7>M4GH;2B590N!(*PITTEUPCP7Y+WC'TN+:A7\N[R 9
M9. 0\*A&2W^K+)V0$ UW-.)2OOJ\HTXBOGR\]REO93O9;I8T1Y[M3IEXW7E?
M5%"D[6;3BWH(/E!)/9'WJ!7MVW0?3_)[^(3'I>_*)UP?_R\L@ 9_KB 6,K9V
M-<[.2)<+\D]WZ  F R8DIG=*!>.L*LEO8SI==D(^;@]586NH?K9=\RMIK(S]
MRC'M]J@7MT;]LT"/NT$=:I-+F 5TPE=\[Z1$P%7I&W'G/CA;PW$Y[D%TG7"<
M)UZ#WQE=/WS9.QX*PB <!4.AEF!(A9<(@'SF>UVUL^PW?S_^<L!&F*_R<#L;
M]T (V8298\7O,8T%%IS)]^XY@1@3E.-U+LI+<69,PG2> 9W9*,5LY@U=AQ%'
M^[4?,;*PQSB1A )K@BX OB3_2!Q5+NSDP:TY8>1HK-="5RY0\A:AV#'B/STM
ME\G:_/KK33CJ@OJ"+GC%X 6T-$2Q?D99:*4-K]2762![G_AK/B!BP *,V%0J
M(O1JRCM(*R>;]@A>".T.%&\,&;A>N)P&-D"XH <QA]!S)Z3';/<!IQD+D1B;
M4V1ZA=B7GCZW422Y!/E4S+& 3,H%2HW&MJ(.<\?2GA()<B+[4SU"T, %-V3@
MATW!,E]D*6$,_0 +.-.PK _1CON [3"=R3'BEI4EMDVXJ63?2&P-A9;#LO!A
MA721J&Q+$QZ,X=N11 9[V40'X=8/U1@KM4KGZG+.+JEB<-#OLA_)I/XAN )F
MP?3)V FB9[FW>]=S7;M'@5$4L#6*&FY:JZZJ7LVX/WXH%N+L]Q-*X0K]4K4
M<< TBCGQ(FOQG3'PYG'A)!""I05P7/<^,LY(XU.'%(KY+%1,/VK+#U+QS4A%
M%VR-"61V!M>@FT%!V]^#2,RQ)J, [55YV&B1C&.:,0JA49J+SL*&D5!P-O96
M.,YG_1[3\\69@Y"]!R&[%0S-#FZQUAODT&41-_W^]L[]MRALFUD?YB=C1B8H
M%*E-%BN!A%J9PE$O_;0RZO=YD-+W+:4M*<=,'&3UQ62UR#+'1^;3RFK09S)9
M?=Y@..)0^U$G$Q"W>FMWQ**."4-10+SR)'KBK6\(.WF:75X[-"[LMQP8EYQ>
MSNRHY<S.JG)[R11^LDS9'9ZQ13YDU!P2TZ92)LM9SV!?F[;>-#]O<#($10E[
MW=QE=SJ"GKY?(K2#;<":(5E@&UYY#Y)#0)@!G+EFWV^MZQO;7; ^O> ;O:E1
MZ&E%LOVY=MTC6/I+YKF2*RJFI#ND E ZJE]VCV0Z_='G!'C###V4X/X8B.QU
M?A?11-LJF,GTNIO#P(5(^^)P(V#R9CTB3ZW;!O]=;5==2\U _?D*:(<K"CKM
MPTPNRD7HVNYRY\/JUFOH+-QGT*YW+^N_D:["S2_75'QEBEQ=K>R"V6M9=G^?
MN.58&#$PTIL24R\6096OH$N9WF2ZM$+#)0%% %$']C(@ ^$^J"$&'AZNVE!)
M+-;GCG\0Q,]HYT_(ZGFN^3&NXBR:0-XZJ^KD=OXDC4N""8.60B\SRP F.SJV
M-&:R. :'26<73T2^$(V:\?/M2V,@D\\2C_O;<<+A/^O1&_[@+QN*O^ATM_J/
M,#EN2(B5&+ZRG#D$>6 V1)0@#XZK;>!8,ET+8 P63?%^(.Y;.7WZ#^=)CV5/
M<? '#D.C;#F ()0(=L\EM ,IHXZ)27-JZOU-6!FO_K&HL*2_7&H]&MP6C^@L
MN(T*2?;)V&I&TC@2/DJ'TOPN@+=PK\&W=^4"?JZ[?D$S.ALMX\A&J5JD"P(&
M'FW\NM9DI7F51)SJ'@,^!J?:?J!3F?+/:> -4C,'W'1M5U0^E/5/=38YDPCF
M_@U1&I =K^QXIISNBI_R#25YR\F3O"W%1CYKE;)Y TW?5JG0Q[RY'7.C-]HG
MT0>K9=8'QX_M7M!MTBL&-PYZ=,O'J3^N"5[ ;9)C4,:4>'I#H@"K0-$28#QF
M$=S\5LA79VTQLZLDQ$GH >E=-@[Y5[W;:-[6S^786Y6#TDD<4;5>.-/Z=PR:
MM-Z^K),K,#7^]INL'M6HDCI8&V^VXV810'3WE(+0#J"$F6=@1"BZ5$/>XXJ4
MRUE#'RC4NX#"\S]!58 9[./L7J/L\@'FQ^UPZ;F79;X[$2Z_$1'^-'-<]'$V
MG]61B0*NVDNNH[EOH,\RM/H=W#<8L[*9?*M2?V2E9V"2IUL,>%/G>]:=!5^?
MMW]\P: \S^J3_=/Z,#WH3%ZD"K-YW#,[NG_F,>"(\YX ?Z7MAIHN:6(XX)*
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M!33LS%$@2J-ZNY$<ZO8@KN,!1%P.:XL.#PP=N38;@"&L.9"1;KJ5O9"/$*;
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M+'/^C[8EO6%KZ(<04ZF4H+]2M;*_7YXDQ_R#,]TKXUD9SQSCN7V> *1G?NA
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M[XP^WCJ].?\5/KQ\N&J?_#]02P$"% ,4    " #$2G]0QB,A\V0#   M#
M$0              @ $     86UR;BTR,#(P,#,S,"YX<V102P$"% ,4
M" #$2G]0(KY1UIL&   +2@  %0              @ &3 P  86UR;BTR,#(P
M,#,S,%]L86(N>&UL4$L! A0#%     @ Q$I_4#J\N178!   A2X  !4
M         ( !80H  &%M<FXM,C R,# S,S!?<')E+GAM;%!+ 0(4 Q0    (
M ,1*?U *)<#A.0\  +YR   .              "  6P/  !D.#4R-#DV9#AK
M+FAT;5!+ 0(4 Q0    ( ,1*?U#3)^$-B1T  '2D   1              "
L =$>  !D.#4R-#DV9&5X.3DQ+FAT;5!+!08     !0 % $ !  ")/      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d852496d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amrn-20200330.xsd" xlink:type="simple"/>
    <context id="duration_2020-03-30_to_2020-03-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2020-03-30_to_2020-03-30"
      id="Hidden_dei_EntityRegistrantName">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2020-03-30_to_2020-03-30"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="duration_2020-03-30_to_2020-03-30"
      id="Hidden_dei_EntityAddressPostalZipCode_duration_2020-03-30_to_2020-03-30">2</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="duration_2020-03-30_to_2020-03-30"
      id="Hidden_dei_CityAreaCode">353 (0)&amp;#160;1</dei:CityAreaCode>
    <dei:AmendmentFlag contextRef="duration_2020-03-30_to_2020-03-30">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-03-30_to_2020-03-30"
      id="Hidden_dei_EntityCentralIndexKey">0000897448</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-03-30_to_2020-03-30">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-03-30_to_2020-03-30">2020-03-30</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-03-30_to_2020-03-30">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-03-30_to_2020-03-30">0-21392</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-03-30_to_2020-03-30">77 Sir John Rogerson&#x2019;s Quay</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-03-30_to_2020-03-30">Block C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2020-03-30_to_2020-03-30">Grand Canal Docklands</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-03-30_to_2020-03-30">Dublin 2</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-03-30_to_2020-03-30">2</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2020-03-30_to_2020-03-30">IE</dei:EntityAddressCountry>
    <dei:LocalPhoneNumber contextRef="duration_2020-03-30_to_2020-03-30">6699 020</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-03-30_to_2020-03-30">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-03-30_to_2020-03-30">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-03-30_to_2020-03-30">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-03-30_to_2020-03-30">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-03-30_to_2020-03-30">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1)&#160;Ordinary Share of Amarin Corporation plc</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-03-30_to_2020-03-30">AMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-03-30_to_2020-03-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-03-30_to_2020-03-30">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M\+L(6Z_-SOQCX[/@T,.ONQB^ %!+ P04    " #$2G]0F5R<(Q &  "<)P
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M2P$"% ,4    " #$2G]0)^B'#H(   "Q    $               @ 'I
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,1*?U B9F@X[@   "L"   1
M              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M ,1*?U"97)PC$ 8  )PG   3              "  ;8"  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ Q$I_4#TB@ NU @  9 P  !@
M     ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M ,1*?U!M$).YMP(  /T&   4              "  >(+  !X;"]S:&%R9613
M=')I;F=S+GAM;%!+ 0(4 Q0    ( ,1*?U"ZH3F*UP$  #(&   -
M      "  <L.  !X;"]S='EL97,N>&UL4$L! A0#%     @ Q$I_4!9M(W]#
M 0  / (   \              ( !S1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( ,1*?U#_P"8(O0   (4"   :              "  3T2  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,1*?U +C]@#(0$
M %<$   3              "  3(3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     *  H @ (  (04      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6628479904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMARIN CORP PLC\UK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">353 (0)&#160;1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000897448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 30,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-21392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">77 Sir John Rogerson&#8217;s Quay<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Block C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Grand Canal Docklands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6699 020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1)&#160;Ordinary Share of Amarin Corporation plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
